The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Casgevy may not bring in bucketloads of revenue right away, as treatment involves a months' long process and the biotech also takes a smaller share of profit than partner Vertex Pharmaceuticals.

A new type of bone marrow transplant can cure sickle cell disease with only half of the donor's cell proteins matching, ...

The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well. Investing in stocks that aren't performing well can be a good move, but only if there are good reasons ...

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...